Neuroendocrine Tumors - Pipeline Review, H1 2020

June 2020 | 795 pages | ID: NCBAD161478EN
Global Markets Direct

Abstracts

Neuroendocrine Tumors - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2020, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.
Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 34, 29, 1, 11, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 3 and 1 molecules, respectively.
Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
• The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Neuroendocrine Tumors - Overview
Neuroendocrine Tumors - Therapeutics Development
Neuroendocrine Tumors - Therapeutics Assessment
Neuroendocrine Tumors - Companies Involved in Therapeutics Development
Neuroendocrine Tumors - Drug Profiles
Neuroendocrine Tumors - Dormant Projects
Neuroendocrine Tumors - Discontinued Products
Neuroendocrine Tumors - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Neuroendocrine Tumors, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Neuroendocrine Tumors - Pipeline by Aadi Bioscience Inc, H1 2020
Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H1 2020
Neuroendocrine Tumors - Pipeline by Akeso Inc, H1 2020
Neuroendocrine Tumors - Pipeline by AnHeart Therapeutics Inc, H1 2020
Neuroendocrine Tumors - Pipeline by Aquestive Therapeutics Inc, H1 2020
Neuroendocrine Tumors - Pipeline by Ascil Proyectos SL, H1 2020
Neuroendocrine Tumors - Pipeline by AstraZeneca Plc, H1 2020
Neuroendocrine Tumors - Pipeline by Beijing Foreland Pharma Co Ltd, H1 2020
Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Neuroendocrine Tumors - Pipeline by BriaCell Therapeutics Corp, H1 2020
Neuroendocrine Tumors - Pipeline by Bristol-Myers Squibb Co, H1 2020
Neuroendocrine Tumors - Dormant Projects, H1 2020
Neuroendocrine Tumors - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neuroendocrine Tumors, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Aadi Bioscience Inc
Advanced Accelerator Applications SA
Akeso Inc
AnHeart Therapeutics Inc
Aquestive Therapeutics Inc
Ascil Proyectos SL
AstraZeneca Plc
Beijing Foreland Pharma Co Ltd
Boehringer Ingelheim International GmbH
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Camurus AB
CanBas Co Ltd
Clarity Pharmaceuticals Pty Ltd
Crinetics Pharmaceuticals Inc
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Eli Lilly and Co
Enterome Bioscience SA
EpicentRx Inc
Esanex Inc
Esperance Pharmaceuticals Inc
Exelixis Inc
GEMoaB Monoclonals GmbH
HEC Pharm Co Ltd
Highlight Therapeutics SL
Hutchison MediPharma Ltd
Innovent Biologics Inc
INVENT Pharmaceuticals Inc
Ipsen SA
Jubilant DraxImage Inc
Karyopharm Therapeutics Inc
Lexicon Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Mateon Therapeutics Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
MimiVax LLC
Mina Therapeutics Ltd
Molecular Targeting Technologies Inc
Molecular Templates Inc
Nanovalent Pharmaceuticals Inc
Northwest Biotherapeutics Inc
Novartis AG
Oncoceutics Inc
Oncology Venture U.S. Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Pfizer Inc
Pharma Mar SA
Pharmathen Global BV
Progenics Pharmaceuticals Inc
Provectus Biopharmaceuticals Inc
Regulaxis SAS
Rhizen Pharmaceuticals SA
Seneca Therapeutics Inc
Shanghai Junshi Bioscience Co Ltd
Sichuan Huiyang Life Science and Technology Corp
Strongbridge Biopharma plc
Suntec Medical (Taiwan) Inc
Taiho Oncology Inc
Tarveda Therapeutics Inc
Teclison Ltd
Trio Medicines Ltd
Vanquish Oncology Inc
Veana Therapeutics LLC
Vyriad Inc
Xencor Inc